US6008217A
(en)
*
|
1995-12-20 |
1999-12-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US5874424A
(en)
*
|
1995-12-20 |
1999-02-23 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US6204261B1
(en)
*
|
1995-12-20 |
2001-03-20 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of interleukin-1β Converting enzyme inhibitors
|
US5714585A
(en)
*
|
1987-10-26 |
1998-02-03 |
Sterling Winthrop, Inc. |
Antibodies that are immunoreactive with interleukin-7
|
US5328988A
(en)
*
|
1987-10-26 |
1994-07-12 |
Immunex Corporation |
Interleukin-7
|
US6511665B1
(en)
*
|
1987-11-25 |
2003-01-28 |
Immunex Corporation |
Antibodies to interleukin-1 receptors
|
US6159460A
(en)
*
|
1988-05-27 |
2000-12-12 |
Amgen Inc. |
Method for treating interleukin-1 mediated diseases
|
US5075222A
(en)
|
1988-05-27 |
1991-12-24 |
Synergen, Inc. |
Interleukin-1 inhibitors
|
US6858409B1
(en)
|
1988-05-27 |
2005-02-22 |
Amgen Inc. |
Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
|
US6384191B1
(en)
|
1989-07-06 |
2002-05-07 |
Regents Of The University Of California |
Receptors for fibroblast growth factors
|
US5106965A
(en)
*
|
1989-11-27 |
1992-04-21 |
Research Corporation Technologies, Inc. |
Detection of human adenovirus
|
ES2137933T3
(es)
*
|
1990-09-28 |
2000-01-01 |
Immunex Corp |
Metodo para producir linfocitos t citotoxicos independientes de th.
|
US5470730A
(en)
*
|
1990-09-28 |
1995-11-28 |
Immunex |
Method for producing TH -independent cytotoxic T lymphocytes
|
WO1992011359A1
(en)
*
|
1990-12-20 |
1992-07-09 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
A truncated interleukin-1 receptor gene for the treatment of arthritis
|
US6413511B1
(en)
|
1990-12-20 |
2002-07-02 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
|
US6228356B1
(en)
|
1990-12-20 |
2001-05-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
|
US6156304A
(en)
*
|
1990-12-20 |
2000-12-05 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Gene transfer for studying and treating a connective tissue of a mammalian host
|
US6159464A
(en)
*
|
1990-12-20 |
2000-12-12 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
|
US5858355A
(en)
*
|
1990-12-20 |
1999-01-12 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
IRAP gene as treatment for arthritis
|
CA2121473C
(en)
*
|
1991-10-15 |
2001-05-01 |
Michael Mullarkey |
Methods and compositions for treating allergic reactions
|
WO1993019777A1
(en)
*
|
1992-03-30 |
1993-10-14 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US6582728B1
(en)
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
US6509006B1
(en)
|
1992-07-08 |
2003-01-21 |
Inhale Therapeutic Systems, Inc. |
Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
|
US6024090A
(en)
|
1993-01-29 |
2000-02-15 |
Aradigm Corporation |
Method of treating a diabetic patient by aerosolized administration of insulin lispro
|
US7448375B2
(en)
|
1993-01-29 |
2008-11-11 |
Aradigm Corporation |
Method of treating diabetes mellitus in a patient
|
US5608035A
(en)
*
|
1994-02-02 |
1997-03-04 |
Affymax Technologies N.V. |
Peptides and compounds that bind to the IL-1 receptor
|
US5861476A
(en)
*
|
1994-02-02 |
1999-01-19 |
Affymax Technologies N.V. |
Peptides and compounds that bind to the IL-1 receptor
|
US5786331A
(en)
*
|
1994-02-02 |
1998-07-28 |
Affymax Technologies N.V. |
Peptides and compounds that bind to the IL-1 receptor
|
US5880096A
(en)
*
|
1994-02-02 |
1999-03-09 |
Affymax Technologies N.V. |
Peptides and compounds that bind to the IL-1 receptor
|
CZ295827B6
(cs)
|
1994-03-07 |
2005-11-16 |
Nektar Therapeutics |
Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
|
US6051256A
(en)
*
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
JPH083058A
(ja)
*
|
1994-06-17 |
1996-01-09 |
Hoechst Japan Ltd |
新規な骨代謝疾患治療剤
|
US5716929A
(en)
*
|
1994-06-17 |
1998-02-10 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1β converting enzyme
|
US5847135A
(en)
*
|
1994-06-17 |
1998-12-08 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US5756466A
(en)
*
|
1994-06-17 |
1998-05-26 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1β converting enzyme
|
US6420522B1
(en)
|
1995-06-05 |
2002-07-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
EP0779923A2
(en)
*
|
1994-09-09 |
1997-06-25 |
Neurocrine Biosciences, Inc. |
Interleukin-1 type 3 receptors
|
US6239268B1
(en)
|
1994-09-09 |
2001-05-29 |
Neurocrine Biosciences, Inc. |
Interleukin-1 type 3 receptors
|
US7091181B2
(en)
|
1994-12-12 |
2006-08-15 |
Omeros Corporation |
Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
|
US5780014A
(en)
*
|
1995-04-14 |
1998-07-14 |
Inhale Therapeutic Systems |
Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
|
KR100510234B1
(ko)
|
1995-06-29 |
2005-11-25 |
임뮤넥스 코포레이션 |
세포소멸을 유도하는 시토킨
|
US5843904A
(en)
*
|
1995-12-20 |
1998-12-01 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1βconverting enzyme
|
US6410252B1
(en)
|
1995-12-22 |
2002-06-25 |
Case Western Reserve University |
Methods for measuring T cell cytokines
|
US5939281A
(en)
*
|
1996-09-16 |
1999-08-17 |
Case Western Reserve University |
Detecting alloreactivity
|
ATE406176T1
(de)
*
|
1996-12-06 |
2008-09-15 |
Amgen Inc |
Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
US6524795B1
(en)
|
1997-03-10 |
2003-02-25 |
Interleukin Genetics, Inc. |
Diagnostics for cardiovascular disorders
|
US7820383B2
(en)
|
1997-03-10 |
2010-10-26 |
Interleukin Genetics, Inc. |
Method for diagnosing myocardial infarction
|
US6384203B1
(en)
|
1999-05-12 |
2002-05-07 |
Immunex Corporation |
Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
|
US6063600A
(en)
*
|
1997-05-23 |
2000-05-16 |
Uab Research Foundation |
DNA encoding canine interleukin-1 receptor antagonist
|
US6733967B1
(en)
|
1998-04-21 |
2004-05-11 |
Interleukin Genetics, Inc. |
Fetal testing for prediction of low birth weight
|
DK1105485T3
(da)
*
|
1998-08-21 |
2006-10-30 |
Immunex Corp |
Human IL-1-epsilon-DNA og polypeptider
|
AU1345000A
(en)
*
|
1998-11-05 |
2000-05-22 |
Omeros Medical Systems, Inc. |
Irrigation solution and method for inhibition of pain and inflammation
|
US20090023147A1
(en)
*
|
1999-08-30 |
2009-01-22 |
Kenneth Kornman |
Diagnostics and therapeutics for osteoporosis
|
US6346247B1
(en)
|
1999-10-28 |
2002-02-12 |
Promega Corporation |
Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
AU782067B2
(en)
|
1999-12-20 |
2005-06-30 |
Immunex Corporation |
TWEAK receptor
|
AR030554A1
(es)
|
2000-03-16 |
2003-08-27 |
Amgen Inc |
Moleculas similares a receptores il-17 y usos de las mismas
|
EP1282435A2
(en)
*
|
2000-05-12 |
2003-02-12 |
Immunex Corporation |
Interleukin-1 inhibitors in the treatment of diseases
|
US7575761B2
(en)
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
US20030040119A1
(en)
*
|
2001-04-11 |
2003-02-27 |
The Regents Of The University Of Michigan |
Separation devices and methods for separating particles
|
US20050152902A1
(en)
*
|
2001-06-05 |
2005-07-14 |
Advanced Biotherapy, Inc. |
Treatment of diabetic retinopathy
|
JP2005500032A
(ja)
*
|
2001-06-15 |
2005-01-06 |
インターリューキン ジェネティックス インコーポレイテッド |
老化関連症状の早期発現を検出および治療する方法
|
EP2087908B1
(en)
|
2001-06-26 |
2018-05-30 |
Amgen Inc. |
Antibodies to opgl
|
MXPA04003057A
(es)
|
2001-10-04 |
2005-06-20 |
Immunex Corp |
Proteina 4 de enlace ul16.
|
CN1753903B
(zh)
*
|
2001-11-19 |
2010-05-12 |
白介素遗传公司 |
影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性
|
US20080311581A1
(en)
*
|
2001-11-19 |
2008-12-18 |
David Wyllie |
Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
|
US20070264645A1
(en)
*
|
2002-01-25 |
2007-11-15 |
Kenneth Kornman |
IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
|
JP2005521401A
(ja)
|
2002-03-27 |
2005-07-21 |
イミュネックス・コーポレーション |
ポリペプチド産生を増加させる方法
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
CA2497884C
(en)
|
2002-09-06 |
2013-10-22 |
Brian Varnum |
Therapeutic human anti-il-1r1 monoclonal antibody
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
WO2004060911A2
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
US20050232931A1
(en)
*
|
2003-06-13 |
2005-10-20 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20040254108A1
(en)
*
|
2003-06-13 |
2004-12-16 |
Jing Ma |
Preparation and application of anti-tumor bifunctional fusion proteins
|
EP1648935A2
(en)
|
2003-07-25 |
2006-04-26 |
Amgen Inc. |
Antagonists and agonists of ldcam and methods of use
|
KR20060061350A
(ko)
*
|
2003-08-08 |
2006-06-07 |
인터레우킨 제네틱스, 인코포레이티드 |
골다공증 진단 및 치료
|
HUE040595T2
(hu)
*
|
2004-04-02 |
2019-03-28 |
Swedish Orphan Biovitrum Ab Publ |
Eljárás IL-1ra aggregációjának csökkentésére
|
US20050276807A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of acne
|
WO2006044263A2
(en)
*
|
2004-10-12 |
2006-04-27 |
Advanced Biotherapy, Inc. |
Treatment of herpes
|
EP1863847A2
(en)
*
|
2004-12-02 |
2007-12-12 |
Domantis Limited |
Anti-il-1r1 single domain antibodies and therapeutic uses
|
WO2007050794A2
(en)
*
|
2005-10-25 |
2007-05-03 |
Interleuken Genetics, Inc. |
The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
BRPI0619224A2
(pt)
*
|
2005-12-01 |
2017-06-20 |
Domantis Ltd |
monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
|
US8129334B2
(en)
|
2006-03-31 |
2012-03-06 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
|
BRPI0716762A2
(pt)
|
2006-09-13 |
2013-09-24 |
Abbott Lab |
melhorias da cultura celular
|
EP2500416A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
ES2431671T3
(es)
*
|
2006-11-15 |
2013-11-27 |
Interleukin Genetics, Inc. |
El complejo génico de IL-1 y resistencia a la insulina: polimorfismos asociados, haplotipos y métodos para usarlos
|
NO2188313T3
(es)
|
2007-08-21 |
2018-03-31 |
|
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
JP2011502510A
(ja)
*
|
2007-11-08 |
2011-01-27 |
インタールーキン ジェネティクス, インコーポレイテッド |
老化に関係がある皮膚疾患の診断
|
EP2304052A2
(en)
*
|
2008-05-02 |
2011-04-06 |
Interleukin Genetics, Inc. |
Detecting genetic predisposition to osteoarthritis associated conditions
|
EP2283156B1
(en)
*
|
2008-05-02 |
2015-11-11 |
Interleukin Genetics, Inc. |
Detecting genetic predisposition to osteoarthritis associated conditions
|
PL3085773T3
(pl)
|
2008-05-30 |
2021-01-11 |
Xbiotech, Inc |
Zastosowanie przeciwciał il-1 alfa
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
CA2780542C
(en)
|
2009-11-13 |
2020-03-24 |
Grifols Therapeutics Inc. |
Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
JP2013528360A
(ja)
|
2010-04-09 |
2013-07-11 |
アムジェン インコーポレイテッド |
Btnl9タンパク質、核酸および抗体ならびにそれらの使用
|
AU2011239689A1
(en)
|
2010-04-15 |
2012-11-08 |
Amgen Inc. |
Human FGF receptor and beta-Klotho binding proteins
|
KR102167261B1
(ko)
|
2010-06-18 |
2020-10-20 |
엑스바이오테크, 인크. |
관절염 치료
|
WO2012019160A1
(en)
|
2010-08-05 |
2012-02-09 |
Amgen Inc. |
Dipeptides to enhance yield and viability from cell cultures
|
AU2011293554B9
(en)
|
2010-08-23 |
2015-03-19 |
Xbiotech Inc. |
Treatment for neoplastic diseases
|
US20140105898A1
(en)
|
2011-02-28 |
2014-04-17 |
Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo |
Apoptosis-inducing molecules and uses therefor
|
US9724409B2
(en)
|
2011-04-01 |
2017-08-08 |
Xbiotech, Inc. |
Treatment of inflammatory skin disease
|
US9133493B2
(en)
|
2011-04-21 |
2015-09-15 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2013006479A2
(en)
|
2011-07-01 |
2013-01-10 |
Amgen Inc. |
Mammalian cell culture
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
US20140315187A1
(en)
|
2011-09-02 |
2014-10-23 |
Amgen Inc. |
Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
|
UA118332C2
(uk)
|
2011-09-22 |
2019-01-10 |
Емджен Інк. |
Білок, що зв'язує антиген cd27l
|
CN104220460A
(zh)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
激动人lcat抗原结合蛋白和它们在疗法中的用途
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
KR101932697B1
(ko)
|
2012-04-27 |
2019-03-21 |
노보 노르디스크 에이/에스 |
사람 cd30 리간드 항원 결합 단백질
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
CA2878400A1
(en)
|
2012-07-19 |
2014-01-23 |
Amgen Inc. |
Btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
AU2013354937B2
(en)
|
2012-12-07 |
2019-09-19 |
North Carolina State University |
Beta-hexosyl-transferases and uses thereof
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
TWI771890B
(zh)
|
2013-03-14 |
2022-07-21 |
美商安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
CA2904337A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
EP3395423B1
(en)
|
2013-03-14 |
2023-09-20 |
Amgen Inc. |
Removal of leaked affinity purification ligand
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
ES2770976T3
(es)
|
2013-03-15 |
2020-07-06 |
Amgen Inc |
Anticuerpos PAC1 humanos
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
AU2014236867A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Methods and compositions relating to anti-CCR7 antigen binding proteins
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
NZ713636A
(en)
|
2013-05-30 |
2022-07-01 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
EP3712166A1
(en)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
WO2015048272A1
(en)
|
2013-09-25 |
2015-04-02 |
Amgen Inc. |
V-c-fc-v-c antibody
|
AU2014342232B2
(en)
|
2013-10-31 |
2017-12-21 |
Amgen Inc. |
Use of monensin to regulate glycosylation of recombinant proteins
|
JP6732660B2
(ja)
|
2014-01-13 |
2020-07-29 |
アムジエン・インコーポレーテツド |
組換えタンパク質の高マンノースグリコフォーム含有量を操作するためのオルニチン代謝の調節
|
KR102410393B1
(ko)
|
2014-01-29 |
2022-06-16 |
암젠 인크 |
재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
RU2019119862A
(ru)
|
2014-02-20 |
2019-07-15 |
Аллерган, Инк. |
Антитела к компоненту комплемента c5
|
SG11201606983SA
(en)
|
2014-02-27 |
2016-09-29 |
Allergan Inc |
COMPLEMENT FACTOR Bb ANTIBODIES
|
JP6695814B2
(ja)
|
2014-06-04 |
2020-05-20 |
アムジエン・インコーポレーテツド |
哺乳類細胞培養物を回収するための方法
|
AU2015318008B2
(en)
|
2014-09-15 |
2021-05-20 |
Amgen Inc. |
Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
|
CA2968372A1
(en)
|
2014-11-19 |
2016-05-26 |
Amgen Inc. |
Quantitation of glycan moiety in recombinant glycoproteins
|
EA036178B1
(ru)
|
2014-12-01 |
2020-10-09 |
Эмджен Инк. |
Процесс контроля уровня содержания гликанов в составе гликопротеинов
|
US10851144B2
(en)
|
2015-04-10 |
2020-12-01 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
CN107787332B
(zh)
|
2015-04-24 |
2022-09-09 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
MA42821A
(fr)
|
2015-09-15 |
2018-07-25 |
Amgen Inc |
Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
|
JP7010812B2
(ja)
|
2015-09-22 |
2022-02-10 |
ジェネンテック, インコーポレイテッド |
Fc含有タンパク質の発現
|
JP6983772B2
(ja)
|
2015-11-02 |
2021-12-17 |
ジェネンテック, インコーポレイテッド |
タンパク質のフコシル化及び脱フコシル化形態の作製方法
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
CR20180378A
(es)
|
2015-12-23 |
2018-12-06 |
Amgen Inc |
Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
|
EP3808764A1
(en)
|
2016-05-04 |
2021-04-21 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
EP3487867A2
(en)
|
2016-07-22 |
2019-05-29 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
US10041044B2
(en)
|
2016-07-29 |
2018-08-07 |
Trustees Of Boston University |
Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
|
CA3043528A1
(en)
|
2016-11-14 |
2018-05-17 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
AU2018206279B2
(en)
|
2017-01-06 |
2020-09-03 |
Abl Bio Inc. |
Anti-alpha-syn antibody and use thereof
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
WO2018150265A1
(en)
|
2017-02-16 |
2018-08-23 |
Xbiotech, Inc. |
Treatment of hidradenitis suppurativa
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
KR20200019122A
(ko)
|
2017-06-20 |
2020-02-21 |
암젠 인크 |
Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
|
WO2019028382A1
(en)
|
2017-08-04 |
2019-02-07 |
Amgen Inc. |
CYS-MABS CONJUGATION METHOD
|
TWI831762B
(zh)
|
2018-01-12 |
2024-02-11 |
美商安進公司 |
Pac1抗體及其用途
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
KR20210101270A
(ko)
|
2018-12-10 |
2021-08-18 |
암젠 인크 |
돌연변이 피기백 트랜스포사제
|
TW202110877A
(zh)
|
2019-05-30 |
2021-03-16 |
美商安進公司 |
工程改造鉸鏈區以驅動抗體二聚化
|
CA3143524A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
EP4385573A2
(en)
|
2019-08-13 |
2024-06-19 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
TW202132340A
(zh)
|
2019-11-04 |
2021-09-01 |
美商安進公司 |
治療白血病之方法
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
WO2021102049A1
(en)
|
2019-11-19 |
2021-05-27 |
Amgen Inc. |
Novel multispecific antibody format
|
CA3162705A1
(en)
|
2019-12-17 |
2021-06-24 |
Amgen Inc. |
Dual interleukin-2 /tnf receptor agonist for use in therapy
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
EP4200338A1
(en)
|
2020-08-20 |
2023-06-28 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
JP2023544769A
(ja)
|
2020-10-07 |
2023-10-25 |
アムジエン・インコーポレーテツド |
多重特異性抗体の構築のためのビルディングブロックの合理的選択
|
TW202233660A
(zh)
|
2020-10-30 |
2022-09-01 |
美商安進公司 |
過表現胰島素樣生長因子受體突變體以調節igf補充
|
WO2022103773A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
JP2024515301A
(ja)
|
2021-04-20 |
2024-04-08 |
アムジエン・インコーポレーテツド |
多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
|
US20240209115A1
(en)
|
2021-04-29 |
2024-06-27 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
MX2023014680A
(es)
|
2021-06-10 |
2024-01-12 |
Amgen Inc |
Variantes genomodificadas de la nrg-1 con una selectividad mejorada frente al erbb4 pero no frente al erbb3.
|
TW202328442A
(zh)
|
2021-09-10 |
2023-07-16 |
美商安進公司 |
平臺宿主對igf—培養基之適應
|
CA3241882A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023172965A1
(en)
|
2022-03-09 |
2023-09-14 |
Amgen Inc. |
Optimized transfection protocol
|